196TiPSGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

196TiPSGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 30; no. Supplement_3
Main Authors: Boni, V, Alemany, C, Meisel, J L, Sinha, R, Sterrenberg, D, Tkaczuk, K H R, Wang, Y, Wang, Z, Han, H S
Format: Journal Article
Language:English
Published: Oxford University Press 01-05-2019
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdz100.047